Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients

Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the one side, this drug can rapidly improve the symptoms related to the hematological disease; on the other side, the inhibition of JAK1/2 can lead to immunosuppression which may increase the risk of infectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Duminuco, Andrea, Scarso, Salvatore, Cupri, Alessandra, Parrinello, Nunziatina Laura, Villari, Loredana, Scuderi, Grazia, Giunta, Giuliana, Leotta, Salvatore, Milone, Giulio Antonio, Giuffrida, Giulia, Palumbo, Giuseppe Alberto, Milone, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866708/
https://www.ncbi.nlm.nih.gov/pubmed/36675507
http://dx.doi.org/10.3390/jcm12020578

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866708/
https://www.ncbi.nlm.nih.gov/pubmed/36675507
http://dx.doi.org/10.3390/jcm12020578

Ejemplares similares